|
High-risk of VTE
|
126 (84)
|
116 (77)
|
0.14^
|
|
Risk factors
| | | |
|
Ischaemic stroke
|
7 (4.7)
|
3 (2)
|
0.19^
|
|
History of VTE
|
15 (10)
|
18 (12)
|
0.58^
|
|
Active cancer
|
4 (2.7)
|
4 (2.7)
|
1.0^
|
|
Decompensated heart failure
|
42 (28)
|
29 (19)
|
0.7^
|
|
Acute on chronic lung disease
|
10 (6.7)
|
10 (6.7)
|
1.0^
|
|
Age > 60 years and immobile
|
107 (71)
|
108 (72)
|
0.89^
|
|
Acute inflammatory disease
|
6 (4)
|
1 (0.7)
|
0.5^
|
|
Multiple additional risk factors
|
21 (14)
|
10 (6.7)
|
0.33^
|
|
Additional risk factors
| | | |
|
Immobility (<60 years)
|
1 (0.7)
|
1 (0.7)
|
0.98^
|
|
Familial history of VTE
|
1 (0.7)
|
0 (0)
|
0.31^
|
|
Oestrogen therapy
|
2 (1.4)
|
1 (0.7)
|
0.55^
|
|
Obesity
|
10 (6.8)
|
7 (4.7)
|
0.43^
|
|
Thrombophilia
|
1 (0.7)
|
0 (0)
|
0.313^
|
|
Active inflammation
|
6 (4.1)
|
2 (1.4)
|
0.09^
|
|
Contraindications
|
48 (32)
|
49 (32.7)
|
0.15^
|
|
Active bleeding
|
5 (3.3)
|
5 (3.3)
|
1.0^
|
|
High risk of bleeding
|
5 (3.3)
|
7 (4.7)
|
0.55^
|
|
Severe hepatic disease
|
1 (0.7)
|
0
|
0.31^
|
|
Heparin induced thrombocytopenia
|
0 (0)
|
0 (0)
| |
|
Current anticoagulation
|
41 (27.3)
|
38 (25.3)
|
0.69^
|
|
Other contraindication
|
0 (0)
|
2 (1.3)
|
0.15^
|
